^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-3845

    i
    Other names: PF-3845
    Company:
    Pfizer
    Drug class:
    FAAH inhibitor
    over3years
    PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo. (PubMed, Int J Mol Sci)
    Furthermore, the administration of PF-3845 decreased the number of osteoclasts and the amount of alveolar bone destruction caused by ligature placement in experimental periodontitis in vivo. The present study provides evidence that PF-3845 is able to suppress osteoclastogenesis and prevent alveolar bone loss, and may give new insights into its role as a treatment for osteoclast-related diseases.
    Preclinical • Journal
    |
    NFATC1 (Nuclear Factor Of Activated T Cells 1)
    |
    PF-3845